P. Unit, European Hospital

, Oncohematological Geriatric Unit. Hôpital Charles-Foix

, Internal Medicine Research and Care Unit, European Hospital

. Médecine-interne, . Européen, and F. Marseille, Phone : (33) 628 325 242 Fax : (33) 413 427 712. E-mail : frederique.retornaz@gmail.com REFERENCES: 1. Inca. Épidémiologie des cancers chez les patients de 65 ans et plus, 2019.

E. Gaetan-des-guetz and . Carola, Cancer colorectal et sujets âgés : y a-t-il une spécificité de prise en charge, Rev Med Suisse, vol.5, pp.1116-1123, 2009.

D. J. Sargent, R. M. Goldberg, S. D. Jacobson, J. S. Macdonald, R. Labianca et al.,

, A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients, New England Journal of Medicine, vol.345, issue.15, pp.1091-1098, 2001.

E. B. Moth, J. Vardy, P. Blinman, and P. Blinman, Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer, Expert Rev Gastroenterol Hepatol, vol.10, issue.12, pp.1321-1361, 2016.

S. Khan, T. A. Alibay, M. Merad, M. Dipalma, B. Raynard et al., Détection et évaluation de la dénutrition en oncologie : quels sont les outils, pour quel type de cancer et dans quels buts, Bulletin du Cancer, vol.103, issue.9, pp.776-85, 2016.

L. St-guily, J. Bouvard, É. Raynard, B. Goldwasser, F. Maget et al., A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer, Journal of Geriatric Oncology, vol.9, issue.1, pp.74-80, 2018.

A. R. Mislang, D. Donato, S. Hubbard, J. Krishna, L. Mottino et al., Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper, Journal of Geriatric Oncology, vol.9, issue.4, pp.382-92, 2018.

S. E. Park, I. G. Hwang, C. H. Choi, H. Kang, B. G. Kim et al., Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy, Medicine (Baltimore), issue.48, p.97, 2018.

M. Barret, C. Berthaud, and J. Taïeb, La sarcopénie : un concept d'importance croissante dans la prise en charge du cancer colorectal. La Presse Médicale, vol.43, pp.628-660, 2014.

C. Handforth, A. Clegg, C. Young, S. Simpkins, M. T. Seymour et al., The prevalence and outcomes of frailty in older cancer patients: a systematic review, Annals of Oncology, vol.26, issue.6, pp.1091-101, 2015.

A. Farcet, L. De-decker, P. V. Rousseau, F. Bergman, H. Molines et al., Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study, vol.11, p.149732, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482501

M. Extermann, M. Aapro, R. Bernabei, J. Cohen, H. Droz et al., Use of comprehensive geriatric assessment in older cancer patients: Contents, Critical Reviews in Oncology/Hematology, p.p, 2005.

M. J. Hassett, S. R. Rao, S. Brozovic, J. E. Stahl, J. H. Schwartz et al.,

, Chemotherapy-Related Hospitalization Among Community Cancer Center Patients. Oncologist, vol.16, issue.3, pp.378-87, 2011.

M. Zauderer, S. Patil, and A. Hurria, Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer, Breast Cancer Res Treat, vol.117, issue.1, 2009.

B. H. Grønberg, S. Sundstrøm, S. Kaasa, R. M. Bremnes, O. Fløtten et al., Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy, Eur J Cancer

A. I. Neugut, M. Matasar, X. Wang, R. Mcbride, J. S. Jacobson et al., Duration of adjuvant chemotherapy for colon cancer and survival among the elderly, J Clin Oncol, vol.24, issue.15, pp.2368-75, 2006.

M. Puts, B. Santos, J. Hardt, J. Monette, V. Girre et al.,

M. E. Hamaker, A. G. Vos, C. H. Smorenburg, S. E. De-rooij, and B. C. Van-munster, The Value of Geriatric Assessments in Predicting Treatment Tolerance and All-Cause Mortality in Older Patients With Cancer. The Oncologist, vol.17, pp.1439-1488, 2012.

T. Aparicio, D. Gargot, and L. Teillet, Geriatric Factors analysis from FFCD

, Phase III Study of First-Line Chemotherapy for elderly Metastatic Colorectal Cancer Patients

, Eur J Cancer, vol.74, pp.98-108, 2017.

T. Kalsi, G. Babic-illman, P. J. Ross, N. R. Maisey, S. Hughes et al., The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people, British Journal of Cancer, vol.112, issue.9, pp.1435-1479, 2015.

P. Chaïbi, N. Magné, S. Breton, A. Chebib, S. Watson et al., Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients, Critical Reviews in Oncology/Hematology, vol.79, issue.3, pp.302-309, 2011.

V. Girre, M. Falcou, M. Gisselbrecht, G. Gridel, V. Mosseri et al., Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol.63, pp.724-754, 2008.

L. P. Fried, C. M. Tangen, J. Walston, A. B. Newman, C. Hirsch et al., Frailty in Older Adults: Evidence for a Phenotype, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol.56, issue.3, pp.146-57, 2001.

F. Retornaz, J. Monette, G. Batist, M. Monette, N. Sourial et al., Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study, The Journals of Gerontology: Series A, vol.63, issue.5, pp.138-187, 2008.

F. Retornaz, F. Rousseau, Y. Morvan, S. Rinaldi, . Nahon et al., Predicting Chemotherapy Toxicity and Death in Older Adults With Colon Cancer: Results of MOST Study, 2018.

P. Soubeyran, M. Fonck, C. Blanc-bisson, J. Blanc, J. Ceccaldi et al., Predictors of early death risk in older patients treated with first-line chemotherapy for cancer, J Clin Oncol, vol.30, issue.15, pp.1829-1863, 2012.

R. Boulahssass, S. Gonfrier, J. Ferrero, M. Sanchez, V. Mari et al., Predicting early death in older adults with cancer, Eur J Cancer, vol.100, pp.65-74, 2018.

S. Katz, Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living, J Am Geriatr Soc, vol.31, issue.12, pp.721-728, 1983.

G. G. Fillenbaum and M. A. Smyer, The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire, J Gerontol, vol.36, issue.4, pp.428-462, 1981.

J. I. Sheikh and J. A. Yesavage, Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version, Clinical Gerontologist: The Journal of Aging and Mental Health, vol.5, issue.1-2, pp.165-73, 1986.

S. Borson, J. M. Scanlan, J. Watanabe, S. Tu, and M. Lessig, Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample, J Am Geriatr Soc, vol.53, issue.5, pp.871-875, 2005.

D. A. Cahn, D. P. Salmon, A. U. Monsch, N. Butters, W. C. Wiederholt et al., Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test, Arch Clin Neuropsychol, vol.11, issue.6, pp.529-568, 1996.

Z. Cook, S. Kirk, S. Lawrenson, and S. Sandford, Use of BMI in the assessment of undernutrition in older subjects: reflecting on practice, Proc Nutr Soc, vol.64, issue.3, pp.313-320, 2005.

F. Retornaz, V. Seux, N. Sourial, A. Braud, J. Monette et al., Comparison of the health and functional status between older inpatients with and without cancer admitted to a geriatric/internal medicine unit, J Gerontol A Biol Sci Med Sci, vol.62, issue.8, pp.917-939, 2007.

C. Falandry, B. Weber, A. Savoye, F. Tinquaut, O. Tredan et al., Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial, Ann Oncol, vol.24, issue.11, pp.2808-2821, 2013.

H. S. Davis, K. Macpherson, H. R. Merry, C. Wentzel, and K. Rockwood, Reliability and validity of questions about exercise in the Canadian Study of Health and Aging, Int Psychogeriatr, vol.13, issue.1, pp.177-82, 2001.

D. Podsiadlo and S. Richardson, Up & Go": a test of basic functional mobility for frail elderly persons, J Am Geriatr Soc, vol.39, issue.2, pp.142-150, 1991.

B. J. Vellas, S. J. Wayne, L. Romero, R. N. Baumgartner, L. Z. Rubenstein et al.,

K. Bandeen-roche, Q. Xue, L. Ferrucci, J. Walston, J. M. Guralnik et al., Phenotype of Frailty: Characterization in the Women's Health and Aging Studies, J Gerontol A Biol Sci Med Sci, vol.61, issue.3, pp.262-268, 2006.

C. Kenis, D. Bron, Y. Libert, L. Decoster, K. V. Puyvelde et al., Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study, Annals of oncology : official journal of the European Society for Medical Oncology, vol.24, issue.5, pp.1306-1318, 2013.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al., Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol, vol.29, issue.25, pp.3457-65, 2011.

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer, vol.118, issue.13, pp.3377-86, 2012.

C. Terret, How and why to perform a geriatric assessment in clinical practice, Annals of Oncology, vol.19, pp.300-303, 2008.

C. Townsley, G. R. Pond, B. Peloza, J. Kok, K. Naidoo et al., Analysis of treatment practices for elderly cancer patients in, J Clin Oncol, vol.23, issue.16, pp.3802-3810, 2005.

C. Fung, W. Dale, S. G. Mohile, C. Fung, S. Gupta et al., Prostate Cancer in the Elderly Patient, J Clin Oncol, vol.32, issue.24, pp.2523-2530, 2014.

N. Sourial, H. Bergman, S. Karunananthan, C. Wolfson, H. Payette et al., Implementing Frailty Into Clinical Practice: A Cautionary Tale, J Gerontol A Biol Sci Med Sci, vol.68, issue.12, pp.1505-1516, 2013.

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer, vol.118, issue.13, pp.3377-86, 2012.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al., Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, Journal of Clinical Oncology, vol.29, issue.25, pp.3457-65, 2011.

. Tncd, Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive

E. François, J. Berdah, E. Chamorey, G. Lesbats, E. Teissier et al., Use of Références Bibliographie : 1. Inca -L'essentiel des faits et chiffres des cancers en France, 2019.

, Inca -Épidémiologie des cancers chez les patients de 65 ans et plus -Oncogériatrie, 2019.

. E-cancer, Patients et proches -Les cancers du côlon -Quelques chiffres, 2017.

. Netgen, Cancer colorectal et sujets âgés : y a-t-il une spécificité de prise en charge ?

. Revue-médicale-suisse, , 2009.

V. Girre, M. Falcou, M. Gisselbrecht, G. Gridel, V. Mosseri et al., Does a

, Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?, J Gerontol A Biol Sci Med Sci, vol.63, issue.7, pp.724-754, 2008.

I. S. Fentiman, U. Tirelli, S. Monfardini, M. Schneider, J. Festen et al., Cancer in the elderly: why so badly treated? Lancet Lond Engl, vol.335, pp.1020-1022, 1990.

, Use of comprehensive geriatric assessment in older cancer patients: Contents, Critical Reviews in Oncology/Hematology, p.p, 2005.

M. Extermann, A comprehensive geriatric intervention detects multiple problems in older breast cancer patients, Crit Rev Oncol Hematol, vol.49, issue.1, pp.69-75, 2004.

P. Chaïbi, N. Magné, S. Breton, A. Chebib, S. Watson et al., Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients, Crit Rev Oncol Hematol, vol.79, issue.3, pp.302-309, 2011.

P. Caillet, F. Canoui-poitrine, J. Vouriot, M. Berle, N. Reinald et al.,

, Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, J Clin Oncol, vol.29, issue.27, pp.3636-3678, 2011.

M. Extermann and A. Hurria, Comprehensive Geriatric Assessment for Older Patients With Cancer, J Clin Oncol, vol.25, issue.14, pp.1824-1855, 2007.

L. Repetto, Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study, J Clin Oncol, vol.20, issue.2, pp.494-502, 2002.

C. Terret, How and why to perform a geriatric assessment in clinical practice

, Oncol, vol.19, pp.300-303, 2008.

C. Townsley, G. R. Pond, B. Peloza, J. Kok, K. Naidoo et al., Analysis of treatment practices for elderly cancer patients in, Holowaty E Straus Siu LL, 2005.

C. Fung, W. Dale, S. G. Mohile, C. Fung, S. Gupta et al., Use of Geriatric Assessment for Older Adults in the Oncology Setting: A Systematic Review, JNCI J Natl Cancer Inst, vol.16, issue.15, pp.1134-64, 2012.

, Hépato-gastro-entérologie -Chirurgie digestive, 4e édition, sous l'égide de la Collégiale des Universitaires en Hépato-gastro-entérologie. ©2018

, © Cancers colorectaux /du diagnostic au suivi, INCa, septembre 2018

S. Olschwang, C. Bonaïti-pellié, J. Feingold, T. Frébourg, S. Grandjouan et al.,

, Prédisposition héréditaire aux cancers du côlon, du rectum et de l'utérus, Pathol Biol, 2006.

, E-cancer. Cancers colorectaux -Les tumeurs du côlon, HAS. Cancer colorectal. Février, vol.54, issue.4, pp.215-244, 2008.

, A genetic model for colorectal tumorigenesis, Fearon ER, 1990.

K. Tariq and K. Ghias, Colorectal cancer carcinogenesis: a review of mechanisms, Cancer Biol Med, vol.13, issue.1, pp.120-155, 2016.

R. Gryfe, B. Bapat, S. Gallinger, C. Swallow, M. Redston et al., Molecular biology of colorectal cancer, Curr Probl Cancer, vol.21, issue.5, pp.233-99, 1997.

M. Toyota, N. Ahuja, M. Ohe-toyota, J. G. Herman, S. B. Baylin et al., CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci, vol.96, issue.15, pp.8681-8687, 1999.

L. Ligue-contre and . Cancer, Cancers du colon et du rectum, pp.10-2017, 2019.

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al.,

, Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors. Rev DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014.

A. Stang and A. Kluttig, Etiologic insights from surface adjustment of colorectal carcinoma incidences: an analysis of the U.S. SEER data, Am J Gastroenterol, 2000.

, TNM Classification of malignant tumours

W. Blackwell, , 2017.

M. A. Maggard, I. Yermilov, J. S. Tomlinson, and C. Y. Ko, Are 12 nodes needed to accurately stage T1 and T2 colon cancers?, Dig Dis Sci, vol.54, issue.3, pp.640-647, 2009.

Z. Wu, G. Qin, N. Zhao, H. Jia, and X. Zheng, Assessing the adequacy of lymph node yield for

M. Gönen, D. Schrag, and M. R. Weiser, Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer, J Clin Oncol, vol.27, issue.36, pp.6166-71, 2009.

J. Phelip and . Snfge, org -Cancer colorectal métastatique, p.75

, Ligue contre le cancer. Cancers colon rectum-Octobre2017, 2019.

J. Gérard, D. Azria, S. Gourgou-bourgade, I. Martel-laffay, C. Hennequin et al.,

L. , Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.10, pp.1638-1682, 2010.

E. Cotte, P. Artru, N. Christou, T. Conroy, J. Doyen et al.,

D. Léonard, N. Meillan, A. Paix, M. Pioche, R. Del-campo et al.,

, Thésaurus National de Cancérologie Digestive, 2019.

. Tncd-|-snfge, org -Société savante médicale française d'hépato-gastroentérologie et

Y. J. Chua, Y. Barbachano, D. Cunningham, J. R. Oates, G. Brown et al.,

, Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial, Lancet Oncol, 2010.

P. Audrey, M. De, L. Louis, and . Jean-louis,

B. Sylvie, D. Delphine, B. Etienne, L. Olivier, R. B. Thierry-;-diasio et al., L'association 5FU/mitomycine C dans le traitement du cancer colorectal métastatique lourdement pré-traité apporte-t-elle un bénéfice ? Résultats d'une étude multicentrique

D. Meulendijks, L. M. Henricks, G. S. Sonke, M. J. Deenen, T. K. Froehlich et al.,

, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and metaanalysis of individual patient data, Lancet Oncol, vol.16, issue.16, pp.1639-50, 2015.

A. Morel, M. Boisdron-celle, F. L. Soulie, P. Craipeau, M. C. Traore et al., Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance, Mol Cancer Ther, vol.5, issue.11, pp.2895-904, 2006.

M. C. Etienne, J. L. Lagrange, O. Dassonville, R. Fleming, A. Thyss et al.,

, Population study of dihydropyrimidine dehydrogenase in cancer-patients, 1994.

A. M. Lee, Q. Shi, E. Pavey, S. R. Alberts, D. J. Sargent et al., DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

M. Boisdron-celle, O. Capitain, R. Faroux, C. Borg, J. Metges et al., JNCI J Natl Cancer Inst, vol.106, issue.12, 2014.

, Prevention of 5-FU-induced toxicities using pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach, J Clin Oncol, vol.31, pp.351-351, 2013.

, INCa et HAS -Recherche d'un deficit en dihydropyrimidine deshydrogenase visant a prevenir certaines toxicites severes-décembre, 2018.

, Common Terminology Criteria for Adverse Events (CTCAE), p.147, 2017.

J. Crawford, D. C. Dale, and G. H. Lyman, Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management, Cancer, vol.100, issue.9, pp.1993-1997, 2004.

S. D. Baker and L. B. Grochow, Pharmacology of cancer chemotherapy in the older person

, Clin Geriatr Med, vol.13, issue.1, pp.169-83, 1997.

S. D. Jacobson, S. Cha, and D. J. Sargent, Tolerability, dose intensity and benefit of 5FU based chemotherapy for advanced colorectal cancer in the elderly. A North Central Cancer Treatment Group Study, Proc Am Soc Clin Oncol, vol.384, 2001.

R. Mattioli, P. Lippe, F. Recchia, C. Massacesi, L. Imperatori et al.,

, Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and 106

, fluorouracil bolus plus continuous infusion, Anticancer Res, vol.21, issue.1A, pp.489-92, 2001.

F. Ghiringhelli, S. Ladoire, P. Manckoundia, B. Chauffert, E. Solary et al.,

, Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l'oncogériatrie une discipline en devenir. Rev Médecine Interne, vol.26, pp.216-241, 2005.

L. Balducci, C. L. Hardy, and G. H. Lyman, Hematopoietic growth factors in the older cancer patient, Curr Opin Hematol, vol.8, issue.3, pp.170-87, 2001.

U. Wedding, F. Honecker, C. Bokemeyer, L. Pientka, and K. Höffken, Tolerance to Chemotherapy in Elderly Patients with Cancer. Cancer Control, vol.14, pp.44-56, 2007.

M. D. Murray and C. M. Callahan, Improving medication use for older adults: an integrated research agenda, Ann Intern Med, vol.139, issue.5, pp.425-434, 2003.

, Résumé des Caractéristiques du Produit : Irinotecan [Internet, 2019.

T. Aparicio, E. Mitry, S. Cunha, A. Girard, and L. , Prise en charge des cancers colorectaux des sujets âgés, Gastroentérologie Clin Biol, vol.29, issue.10, pp.1014-1037, 2005.

G. Milano, M. C. Etienne, E. Cassuto-viguier, A. Thyss, J. Santini et al.,

, Influence of sex and age on fluorouracil clearance, J Clin Oncol, vol.10, issue.7, pp.1171-1176, 1992.

R. M. Goldberg, I. Tabah-fisch, H. Bleiberg, A. De-gramont, C. Tournigand et al.,

, Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer, J Clin Oncol, 2006.

T. Aparicio, A. Navazesh, I. Boutron, N. Bouarioua, D. Chosidow et al.,

T. J. Iwashyna and E. B. Lamont, Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, issue.19, pp.3992-4000, 2002.

M. Extermann, H. Chen, A. B. Cantor, M. B. Corcoran, J. Meyer et al., Predictors of tolerance to chemotherapy in older cancer patients, Eur J Cancer, vol.38, issue.11, pp.1466-73, 2002.

S. Monfardini and B. Chabner, Joint NCI-EORTC consensus meeting on neoplasia in the elderly, Eur J Cancer Oxf Engl, pp.15-16, 1990.

B. N. Stein, N. J. Petrelli, H. O. Douglass, D. L. Driscoll, G. Arcangeli et al., Age and
URL : https://hal.archives-ouvertes.fr/hal-01382787

M. T. Nobile, M. C. Barzacch, O. Sanguineti, S. Chiara, A. Gozza et al., Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer

, Anticancer Res, vol.18, issue.1B, pp.517-538, 1998.

S. Chiara, M. T. Nobile, M. Vincenti, R. Lionetto, A. Gozza et al., Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy, Cancer Chemother Pharmacol, vol.42, issue.4, pp.336-376, 1998.

D. J. Sargent, R. M. Goldberg, S. D. Jacobson, J. S. Macdonald, R. Labianca et al.,

, A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients

, N Engl J Med, vol.345, issue.15, pp.1091-1098, 2001.

A. De-gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi et al., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, issue.16, pp.2938-2985, 2000.

E. François, J. Berdah, E. Chamorey, G. Lesbats, E. Teissier et al., Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study, Cancer Chemother Pharmacol, 2008.

J. Feliu, P. Escudero, F. Llosa, M. Bolaños, J. Vicent et al., Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.13, pp.3104-3115, 2005.

C. Twelves, A. Wong, M. P. Nowacki, M. Abt, H. Burris et al., Capecitabine as adjuvant treatment for stage III colon cancer, N Engl J Med, vol.352, issue.26, pp.2696-704, 2005.

, Etat des lieux et perspectives en oncogériatrie, 2009.

S. Mani, J. Knost, J. Gibbons, J. Garcia, D. Sciortino et al., Phase II trial of prolonged infusion gemcitabine (Gemzar) in advanced colorectal carcinoma : in vivo proof of a pharmacologic principle, Ann Oncol, vol.9, issue.2, p.156, 1998.

C. Delbaldo, S. Faivre, and E. Raymond, Les inhibiteurs des récepteurs de l'Epidermal Growth Factor (EGF), vol.24, pp.372-83, 2003.

F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen, Addition of Bevacizumab to

, Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials, J Clin Oncol, vol.27, issue.2, pp.199-205, 2009.

M. E. Hamaker, B. Van-rixtel, P. Thunnissen, A. H. Oberndorff, and N. Smakman, Ten Bokkel Huinink D. Multidisciplinary decision-making on chemotherapy for colorectal cancer: an agebased comparison, J Geriatr Oncol, vol.6, issue.3, pp.225-257, 2015.

E. Mitry, F. Rollot, V. Jooste, B. Guiu, C. Lepage et al., Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in 109 population-based studies?, Eur J Cancer Oxf Engl, vol.49, issue.13, pp.2919-2944, 1990.

E. Paillaud, P. Caillet, M. Laurent, S. Bastuji-garin, E. Liuu et al.,

, Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment, Clin Interv Aging, 1645.

R. Yancik, M. N. Wesley, L. A. Ries, R. J. Havlik, S. Long et al., Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study, Critical Reviews in Oncology/Hematology, vol.82, issue.11, pp.241-252, 1998.

A. G. Pallis, U. Wedding, D. Lacombe, P. Soubeyran, and H. Wildiers, Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know?, Eur J Cancer, vol.46, issue.6, pp.1019-1044, 2010.

O. Saint-jean and J. Leguen,

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al.,

, Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol, vol.29, issue.25, pp.3457-65, 2011.

M. Extermann, I. Boler, R. Reich, G. H. Lyman, R. H. Brown et al.,

, Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation, J Clin Oncol, vol.28, issue.15_suppl, pp.9000-9000, 2010.

S. G. Mohile, W. Dale, M. R. Somerfield, M. A. Schonberg, C. M. Boyd et al.,

, Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology, J Clin Oncol, 2018.

F. Pamoukdjian, E. Liuu, P. Caillet, M. Gisselbrecht, S. Herbaud et al., L'évaluation gériatrique et les scores pronostiques chez le patient âgé atteint de cancer : une aide à la décision thérapeutique ?, Bull Cancer, vol.104, issue.11, pp.946-55, 2017.

D. Podsiadlo and S. Richardson, Up & Go": a test of basic functional mobility for frail elderly persons, J Am Geriatr Soc, vol.39, issue.2, pp.142-150, 1991.

S. Studenski, S. Perera, K. Patel, C. Rosano, K. Faulkner et al., Gait Speed and Survival in Older Adults, JAMA, vol.305, issue.1, pp.50-58, 2011.

S. Katz, Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living, J Am Geriatr Soc, vol.31, issue.12, pp.721-728, 1983.

G. G. Fillenbaum and M. A. Smyer, The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire, J Gerontol, vol.36, issue.4, pp.428-462, 1981.

M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 1982.

M. F. Folstein, S. E. Folstein, and P. R. Mchugh, Mini-mental state": A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, vol.12, issue.3, pp.189-98, 1975.

S. Borson, J. M. Scanlan, J. Watanabe, S. Tu, and M. Lessig, Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample, J Am Geriatr Soc, vol.53, issue.5, pp.871-875, 2005.

Z. S. Nasreddine, N. A. Phillips, V. Bédirian, S. Charbonneau, V. Whitehead et al.,

, MoCA: a brief screening tool for mild cognitive impairment, The Montreal Cognitive Assessment, vol.53, issue.4, pp.695-704, 2005.

D. A. Cahn, D. P. Salmon, A. U. Monsch, N. Butters, W. C. Wiederholt et al.,

, Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test, Arch Clin Neuropsychol Off J Natl Acad Neuropsychol, vol.11, issue.6, pp.529-568, 1996.

J. I. Sheikh and J. A. Yesavage, Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version, Clin Gerontol J Aging Ment Health, vol.5, issue.1-2, pp.165-73, 1986.

A. S. Zigmond and R. P. Snaith, The hospital anxiety and depression scale, Acta Psychiatr Scand, vol.67, issue.6, pp.361-70, 1983.

F. Retornaz, V. Seux, N. Sourial, A. Braud, J. Monette et al., Comparison of the health and functional status between older inpatients with and without cancer admitted to a geriatric/internal medicine unit, J Gerontol A Biol Sci Med Sci, vol.62, issue.8, pp.917-939, 2007.

M. D. Miller and . Ta, A manual of guidelines for scoring the cumulative illness rating scale for geriatrics, Pittsbg Pa Univ Pittsburgh, 1991.

H. Quan, B. Li, C. M. Couris, K. Fushimi, P. Graham et al., Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries, Am J Epidemiol, vol.173, issue.6, pp.676-82, 2011.

Y. Guigoz, THE MINI NUTRITIONAL ASSESSMENT (MNA®) REVIEW OF THE LITERATURE -WHAT DOES IT TELL US?, J Nutr, vol.10, issue.6, p.23, 2006.

C. Falandry, B. Weber, A. Savoye, F. Tinquaut, O. Tredan et al., Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial, Ann Oncol Off J Eur Soc Med Oncol, 2013.

T. Aparicio, J. Jouve, L. Teillet, D. Gargot, F. Subtil et al., Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients, vol.10, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02088193

M. J. Hassett, S. R. Rao, S. Brozovic, J. E. Stahl, J. H. Schwartz et al.,

, Chemotherapy-Related Hospitalization Among Community Cancer Center Patients. The Oncologist, vol.16, pp.378-87, 2011.

M. Zauderer, S. Patil, and A. Hurria, Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer, Breast Cancer Res Treat, vol.117, issue.1, 2009.

B. H. Grønberg, S. Sundstrøm, S. Kaasa, R. M. Bremnes, O. Fløtten et al., Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy, Eur J Cancer Oxf Engl, vol.46, issue.12, pp.2225-2259, 1990.

A. I. Neugut, M. Matasar, X. Wang, R. Mcbride, J. S. Jacobson et al., Duration of adjuvant chemotherapy for colon cancer and survival among the elderly, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, issue.15, pp.2368-75, 2006.

K. M. Clough-gorr, A. E. Stuck, S. S. Thwin, and R. A. Silliman, Older Breast Cancer Survivors: Geriatric Assessment Domains Are Associated With Poor Tolerance of Treatment Adverse Effects and Predict Mortality Over 7 Years of Follow-Up, J Clin Oncol, vol.28, issue.3, pp.380-386, 2010.

, Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly, Acta Oncologica, vol.55, issue.1, 2019.

C. Kenis, D. Bron, Y. Libert, L. Decoster, K. V. Puyvelde et al., Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study, Ann Oncol Off J Eur Soc Med Oncol, vol.24, issue.5, pp.1306-1318, 2013.

L. Decoster, C. Kenis, K. Van-puyvelde, J. Flamaing, G. Conings et al., The influence of clinical assessment (including age) and geriatric assessment on treatment decisions 113 in older patients with cancer, J Geriatr Oncol, vol.4, issue.3, pp.235-276, 2013.

N. M. Verweij, E. Souwer, A. Schiphorst, H. A. Maas, J. Portielje et al., J Colorectal Dis, vol.32, issue.11, pp.1625-1634, 2017.

S. Karunananthan, H. Bergman, I. Vedel, and F. Retornaz, La fragilité : en quête d'un nouveau paradigme clinique et de recherche pertinent, Rev Médecine Interne, vol.30, issue.2, pp.105-114, 2009.

F. Retornaz, I. Potard, C. Molines, and F. Rousseau, Qu'est-ce que la fragilité en oncogériatrie ? Oncologie, vol.13, pp.73-80, 2011.

T. M. Gill, E. A. Gahbauer, H. G. Allore, and L. Han, Transitions between frailty states among community-living older persons, Arch Intern Med, vol.166, issue.4, pp.418-441, 2006.

D. B. Hogan, Models, Definitions, and Criteria for Frailty

, Conn's Handbook of Models for Human Aging

M. J. Chin-a-paw, J. M. Dekker, E. J. Feskens, E. G. Schouten, and D. Kromhout, How to select a frail elderly population? A comparison of three working definitions, J Clin Epidemiol, 1999.

W. J. Strawbridge, S. J. Shema, J. L. Balfour, H. R. Higby, and G. A. Kaplan, Antecedents of frailty over three decades in an older cohort, J Gerontol B Psychol Sci Soc Sci, vol.53, issue.1, pp.9-16, 1998.

M. Chin-a-paw, L. De-groot, S. V. Van-gend, M. Schoterman, and E. G. Schouten,

M. Schroll, Inactivity and weight loss: effective criteria to identify frailty, J Nutr Health Aging, vol.7, issue.1, pp.55-60, 2003.

, Disability and frailty among elderly Canadians: a comparison of six surveys, Int Psychogeriatr, vol.13, issue.1, pp.159-67, 2001.

L. P. Fried, C. M. Tangen, J. Walston, A. B. Newman, C. Hirsch et al., Frailty in Older Adults: Evidence for a Phenotype, J Gerontol A Biol Sci Med Sci, vol.56, issue.3, pp.146-57, 2001.

D. Kuh, New Dynamics of Ageing (NDA) Preparatory Network. A life course approach to healthy aging, frailty, and capability, J Gerontol A Biol Sci Med Sci, vol.62, issue.7, pp.717-738, 2007.

K. Rockwood, X. Song, C. Macknight, H. Bergman, D. B. Hogan et al., A global clinical measure of fitness and frailty in elderly people, CMAJ Can Med Assoc J, 2005.

, Aug, vol.30, issue.5, pp.489-95

K. E. Ensrud, S. K. Ewing, B. C. Taylor, H. A. Fink, P. M. Cawthon et al., Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women, Arch Intern Med, vol.168, issue.4, pp.382-391, 2008.

F. Retornaz, J. Monette, G. Batist, M. Monette, N. Sourial et al., Usefulness of Frailty Markers in the Assessment of the Health and Functional Status of Older Cancer Patients Referred for Chemotherapy: A Pilot Study, J Gerontol Ser A, vol.63, issue.5, pp.518-540, 2008.

A. Farcet, L. De-decker, P. V. Rousseau, F. Bergman, H. Molines et al., Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study, vol.11, p.149732, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482501

D. Saliba, M. Elliott, L. Z. Rubenstein, D. H. Solomon, R. T. Young et al., The Vulnerable Elders Survey: A Tool for Identifying Vulnerable Older People in the Community

, J Am Geriatr Soc, vol.49, issue.12, pp.1691-1700, 2001.

L. C. Min, M. N. Elliott, N. S. Wenger, and D. Saliba, Higher Vulnerable Elders Survey Scores Predict Death and Functional Decline in Vulnerable Older People, J Am Geriatr Soc, vol.54, issue.3, pp.507-518, 2006.

K. Rockwood, What would make a definition of frailty successful? Age Ageing, 2005.

J. E. Morley, H. M. Perry, and D. K. Miller, Something About Frailty, J Gerontol A Biol Sci Med Sci, vol.57, issue.11, pp.698-704, 2002.

H. Bergman, F. Béland, S. Karunananthan, S. Hummel, D. Hogan et al.,

, Développement d'un cadre de travail pour comprendre et étudier la fragilité, Gerontol Soc, vol.27, issue.2, pp.15-29, 2004.

H. Bergman, L. Ferrucci, J. Guralnik, D. B. Hogan, S. Hummel et al., Frailty: An Emerging Research and Clinical Paradigm--Issues and Controversies, J Gerontol A Biol Sci Med Sci, vol.62, issue.7, pp.731-738, 2007.

M. Puts, P. Lips, and D. Deeg, Static and dynamic measures of frailty predicted decline in performance-based and self-reported physical functioning, J Clin Epidemiol, vol.58, issue.11, pp.1188-98, 2005.

I. Arveux, G. Faivre, L. Lenfant, P. Manckoundia, F. Mourey et al., Le sujet âgé fragile. La Revue de Gériatrie, vol.27, pp.569-581

R. Gonthier, Le concept de fragilité : pourquoi est-il essentiel ? La Revue de Gériatrie, vol.25, pp.135-138, 2000.

P. B. Soeters, P. Reijven, M. Van-bokhorst-de-van-der-schueren, J. Schols, R. Halfens et al., A rational approach to nutritional assessment, Clin Nutr

F. Bozzetti, Evidence-based nutritional support of the elderly cancer patient, Nutrition

P. Senesse and M. Vasson, Nutrition chez le patient adulte atteint de cancer : quand et comment évaluer l'état nutritionnel d'un malade atteint de cancer ? Comment faire le diagnostic de dénutrition et le diagnostic de dénutrition sévère chez un malade atteint de cancer ? Quelles sont les situations les plus à risque de dénutrition ?, Nutr Clin Métabolisme, 2012.

K. Fearon, F. Strasser, S. D. Anker, I. Bosaeus, E. Bruera et al., Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, 2011.

S. Khan, T. A. Alibay, M. Merad, M. Dipalma, B. Raynard et al., Détection et évaluation de la dénutrition en oncologie : quels sont les outils, pour quel type de cancer et dans quels buts, Bull Cancer, vol.103, issue.9, pp.776-85, 2016.

J. Arends, V. Baracos, H. Bertz, F. Bozzetti, P. C. Calder et al., ESPEN expert group recommendations for action against cancer-related malnutrition, Clin Nutr, 2017.

M. Pressoir, S. Desné, D. Berchery, G. Rossignol, B. Poiree et al., Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres

, Br J Cancer, vol.102, issue.6, pp.966-71, 2010.

L. St-guily, J. Bouvard, É. Raynard, B. Goldwasser, F. Maget et al., A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer, J Geriatr Oncol, vol.9, issue.1, pp.74-80, 2018.

J. A. Palesty and S. J. Dudrick, What We Have Learned about Cachexia in Gastrointestinal Cancer, Dig Dis, vol.21, issue.3, pp.198-213, 2003.

D. J. Murry, L. Riva, and D. G. Poplack, Impact of nutrition on pharmacokinetics of antineoplastic agents, p.4

R. Rajeswari, P. A. Shetty, B. P. Gothoskar, P. N. Akolkar, and S. V. Gokhale, Pharmacokinetics of methotrexate in adult Indian patients and its relationship to nutritional status, Cancer Treat Rep

R. Fleming, G. Milano, M. Etienne, N. Renée, A. Thyss et al., No effect of dose, hepatic function

. -fu-infusion, Br J Cancer, vol.66, issue.4, pp.668-72, 1992.

H. Andreyev, A. R. Norman, J. Oates, and D. Cunningham, Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, vol.34, issue.4, pp.503-512, 1998.

M. M. Mcmahon, E. Nystrom, C. Braunschweig, J. Miles, and C. A. Compher, Clinical Guidelines. J Parenter Enter Nutr, vol.37, issue.1, pp.23-36, 2013.

P. Senesse, Nutrition en oncogériatrie. Cancer/Radiothérapie, vol.13, pp.628-659, 2009.

G. Les, , 2018.

L. Joque and A. Jatoi, Total parenteral nutrition in cancer patients: why and when?, Nutr Clin Care Off Publ Tufts Univ, vol.8, issue.2, pp.89-92, 2005.

S. Ikeda, H. Yoshioka, S. Ikeo, M. Morita, N. Sone et al., Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced nonsmall cell lung cancer patients with poor performance status. BMC Cancer, vol.17, p.6, 2017.

A. J. Cruz-jentoft, J. P. Baeyens, J. M. Bauer, Y. Boirie, T. Cederholm et al., European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People, vol.39, pp.412-435, 2010.

T. N. Kim and K. M. Choi, Sarcopenia: Definition, Epidemiology, and Pathophysiology, J Bone Metab, vol.20, issue.1, p.1, 2013.

Y. Rolland, B. Vellas, and . La-sarcopénie, Rev Médecine Interne, vol.30, 2009.

D. R. Thomas, Loss of skeletal muscle mass in aging: Examining the relationship of starvation, sarcopenia and cachexia

A. A. Narsale and J. A. Carson, Role of IL-6 In Cachexia -Therapeutic Implications, Curr Opin Support Palliat Care, vol.8, issue.4, pp.321-328, 2014.

L. M. Wakefield and C. S. Hill, Beyond TGF?: roles of other TGF? superfamily members in cancer, Nat Rev Cancer, vol.13, issue.5, pp.328-369, 2013.

S. Wildi, Overexpression of activin A in stage IV colorectal cancer, Gut, vol.49, issue.3, pp.409-426, 2001.

, Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease | Elsevier Enhanced Reader, 2019.

M. Hilmi, A. Jouinot, R. Burns, F. Pigneur, R. Mounier et al., Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? Pharmacol Ther, vol.196, pp.135-59, 2019.

C. Owusu, S. Margevicius, M. Schluchter, S. M. Koroukian, and N. A. Berger, Short Physical Performance Battery, Usual Gait Speed, Grip Strength and Vulnerable Elders Survey Each Predict Functional Decline among Older Women with Breast Cancer, J Geriatr Oncol, 2017.

T. Veni, S. Boyas, B. Beaune, H. Bourgeois, A. Rahmani et al., Handgrip fatiguing exercise can provide objective assessment of cancer-related fatigue: a pilot study

, Support Care Cancer, vol.27, pp.229-267, 2019.

R. D. Kilgour, A. Vigano, B. Trutschnigg, E. Lucar, M. Borod et al., Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer, vol.21, pp.3261-70, 2013.

S. Cousin, A. Hollebecque, S. Koscielny, O. Mir, A. Varga et al., Low skeletal muscle is associated with toxicity in patients included in phase I trials, Invest New Drugs, 2014.

, Apr, vol.32, issue.2, pp.382-389

F. Mazzuca, C. E. Onesti, M. Roberto, D. Girolamo, M. Botticelli et al., Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines

, Oncotarget, vol.9, issue.39, 2018.

R. Ali, V. E. Baracos, M. B. Sawyer, L. Bianchi, S. Roberts et al., Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens, Cancer Med, vol.5, issue.4, pp.607-623, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01881582

M. Barret, S. Antoun, C. Dalban, D. Malka, T. Mansourbakht et al., Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer, Nutr Cancer

C. Prado, V. E. Baracos, L. J. Mccargar, M. Mourtzakis, K. E. Mulder et al.,

, Body Composition as an Independent Determinant of 5-Fluorouracil-Based Chemotherapy Toxicity. Clin Cancer Res, vol.13, pp.3264-3272, 2007.

P. Soubeyran, M. Fonck, C. Blanc-bisson, J. Blanc, J. Ceccaldi et al., Predictors of early death risk in older patients treated with first-line chemotherapy for cancer

, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.15, pp.1829-1863, 2012.

M. Puts, J. Monette, V. Girre, C. Pepe, M. Monette et al., Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study, Crit Rev Oncol Hematol, 2011.

A. Hurria, S. Gupta, M. Zauderer, E. L. Zuckerman, H. J. Cohen et al., Developing a cancer-specific geriatric assessment, Cancer, vol.104, issue.9, 1998.

T. M. Gill, E. A. Gahbauer, H. G. Allore, and L. Han, Transitions Between Frailty States Among Community-Living Older Persons, Arch Intern Med, vol.166, issue.4, pp.418-441, 2006.

F. Retornaz, M. D. Rousseau, M. D. Morvan, Y. Rinaldi, M. D. Nahon et al.,

R. Castagna, M. D. Boulahssass, M. D. Grino, and M. D. Gholam, Predicting Chemotherapy Toxicity and Death in Older Adults With Colon Cancer: Results of MOST Study, Am Soc Clin Oncol Chic, 2018.

R. Boulahssass, S. Gonfrier, J. Ferrero, M. Sanchez, V. Mari et al.,

, Predicting early death in older adults with cancer, Eur J Cancer, vol.100, pp.65-74, 2018.

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer, vol.118, issue.13, pp.3377-86, 2012.

N. Sourial, H. Bergman, S. Karunananthan, C. Wolfson, H. Payette et al., Implementing Frailty Into Clinical Practice: A Cautionary Tale, J Gerontol Ser A

N. Hébert-croteau, J. Brisson, J. Latreille, M. Rivard, N. Abdelaziz et al.,

S. H. Giordano, G. N. Hortobagyi, S. Kau, R. L. Theriault, and M. L. Bondy, Breast cancer treatment guidelines in older women, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.4, pp.783-91, 2005.

J. S. Goodwin, J. M. Samet, and W. C. Hunt, Determinants of Survival in Older Cancer Patients

, JNCI J Natl Cancer Inst, vol.88, issue.15, pp.1031-1039, 1996.

C. Bouchardy, E. Rapiti, G. Fioretta, P. Laissue, I. Neyroud-caspar et al.,

, Undertreatment Strongly Decreases Prognosis of Breast Cancer in Elderly Women, J Clin Oncol, vol.21, pp.3580-3587, 2003.

A. Hurria, S. Mohile, A. Gajra, H. Klepin, H. Muss et al., Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer, J Clin Oncol, 2016.

, Jul, vol.10, issue.20, pp.2366-71

J. Souglakos, A. Pallis, S. Kakolyris, D. Mavroudis, N. Androulakis et al., Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial, Oncology, vol.69, issue.5, pp.384-90, 2005.

I. Chau, A. R. Norman, D. Cunningham, J. S. Waters, C. Topham et al.,

, Br J Cancer, vol.91, issue.8, pp.1453-1461, 2004.

L. F. Hutchins, J. M. Unger, J. J. Crowley, C. A. Coltman, and K. S. Albain, Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials, N Engl J Med, vol.341, issue.27, pp.2061-2068, 1999.

E. R. Bremberg, M. Pharm, C. H. Md, H. E. Phd, and S. E. Phd,

S. Shah, J. Dowell, and S. Greene, Evaluation of Clinical Pharmacy Services in a

, Hematology/Oncology Outpatient Setting. Ann Pharmacother, vol.40, issue.9, pp.1527-1560, 2006.

A. S. Fabiá, E. C. Rodrigo, A. A. Marí, D. A. Cubells, J. Torres et al., Pharmaceutical validation as a process of improving the quality of antineoplastic treatment, J Oncol Pharm Pract, vol.11, issue.2, pp.45-50, 2005.

S. Ahmed, I. Ahmad, T. Zhu, F. P. Arnold, G. Faiz-anan et al., Early discontinuation but not the timing of adjuvant therapy affects survival of patients with highrisk colorectal cancer: a population-based study, Dis Colon Rectum, vol.53, issue.10, pp.1432-1440, 2010.

L. Ferrucci, J. M. Guralnik, C. Cavazzini, S. Bandinelli, F. Lauretani et al., The frailty syndrome: a critical issue in geriatric oncology, Crit Rev Oncol Hematol, 2003.

, Rôle du facteur tissulaire dans les métastases hépatiques du cancer colo-rectal : vers une nouvelle cible thérapeutique? -PDF [Internet, 2019.

J. Phelip and . Oncopaca--tncd--chapitre, Cancer colorectal métastatique, vol.4

, +/-bévacizumab 5 mg/kg (Avastin®) avec schéma de 5FU modifié (recommandation : grade B)

?. Capecitabine, Xeloda®) (recommandation : grade A)

, 5mg/kg (recommandation : gradeB), vol.7

, ? FOLFIRI (irinotécan 180 mg/m 2 -LV5FU2 simplifié) (recommandation : grade A)

, bévacizumab 5mg/kg (recommandation : gradeB)

, puis 250mg/m 2 hebdomadaire si statut tumoral RAS non muté (recommandation : grade B). Possibilité d'administrer une double dose (500 mg/m 2 ) toutes les deux semaines (recommandation : grade B)

, mg/kg si le statut tumoral RAS est non muté (recommandation : grade C)

, ? FOLFOX 4 simplifié (oxaliplatine 85 mg/m2-LV5FU2 simplifié) (recommandation : grade A)

, +/-bévacizumab 5 mg/kg (recommandation : grade B)

, mg/kg si le statut tumoral RAS est non muté (recommandation : grade B)

, 400 mg/m2 puis 250 mg/m 2 hebdomadaire si statut tumoral RAS non muté. Possibilité d'administrer une double dose (500 mg/m 2 ) toutes les deux semaines (recommandation : grade C)

?. Folfoxiri, irinotécan 165 mg/m 2 -oxaliplatine 85 mg/m 2 -Ac Folinique 200

, ? FOLFOX 7 (oxaliplatine 130mg/m2 -LV5FU2 simplifié sans 5FU bolus) 6 cures puis LV5FU2 simplifié puis réintroduction de l'oxaliplatine à la progression (stratégie OPTIMOX 1) (recommandation : grade B)

?. Xelox, recommandation : grade A) +/-bévacizumab 7,5 mg/kg (recommandation : grade B)

S. Borson, The mini-cog: a cognitive "vitals signs" measure for dementia screening in multi-lingual elderly, Items 1. Etes-vous satisfait(e) de votre vie? Oui Non*, vol.15, p.1021, 2000.

, Avez-vous renoncé à un grand nombre de vos activités? Oui* Non

, Avez-vous l'impression que votre vie est vide? Oui* Non

, Vous ennuyez-vous souvent? Oui* Non

, Envisagez-vous l'avenir avec optimisme? Oui Non*

, Etes-vous souvent préoccupé(e) par des pensées qui reviennent sans cesse? Oui* Non

, Etes-vous de bonne humeur la plupart du temps? Oui Non*

, Craignez-vous un mauvais présage pour l'avenir? Oui* Non

, Etes-vous heureux(se) la plupart du temps Oui Non*

, Vous sentez-vous souvent nerveux(se) au point de ne pouvoir tenir en place? Oui* Non 12. Préférez-vous rester seul(e) dans votre chambre plutôt que d'en sortir Oui* Non, Avez-vous souvent besoin d'aide? Oui* Non 11

, Pensez-vous que votre mémoire est plus mauvaise que celle de la plupart des gens? Oui* Non, L'avenir vous inquiète-t-il? Oui* Non, vol.14

, Pensez-vous qu'il est merveilleux de vivre à notre époque? Oui Non*

*. Avez-vous-souvent-le-cafard?-oui and . Non,

, Avez-vous le sentiment d'être désormais inutile? Oui* Non

. Ressassez-vous-beaucoup-le-passé, Oui* Non 19. Trouvez-vous que la vie est passionnante? Oui Non*

, Avez-vous des difficultés à entreprendre de nouveaux projets? Oui* Non

, Désespérez-vous de votre situation présente? Oui* Non 23. Pensez-vous que la situation des autres est meilleure que la votre Oui* Non 24. Etes-vous souvent irrité(e) par des détails? Oui* Non 25. Eprouvez-vous souvent le besoin de pleurer, Avez-vous beaucoup d'énergie? Oui Non* 22

, Etes-vous content(e) de vous lever le matin? Oui Non* 28. Refusez-vous souvent les activités proposées? Oui* Non 29. Vous est-il facile de prendre des décisions, Avez-vous du mal à vous concentrer? Oui* Non 27

, Avez-vous l'esprit aussi clair qu'autrefois? Oui Non*

, Aucun problème: Aucune pathologie n'affecte ce système ou problèmes médicaux antérieurs sans importance clinique

, Problème léger: Problème actuel léger ou problème antérieur important

, Problème modéré: Atteinte ou morbidité modéré/e et/ou nécessitant un traitement

, Problème sévère: Pathologie sévère et/ou atteinte constante et invalidante et/ou maîtrise des problèmes chroniques difficile

, Problème très grave: Pathologie extrêmement sévère et/ou traitement immédiat requis et/ou défaillance d'un organe et /ou incapacité fonctionnelle grave

B. Vellas, H. Villars, and G. Abellan, Overview of the MNA® -Its History and Challenges, J Nut Health Aging, vol.10, pp.456-465, 2006.

L. Z. Rubenstein, J. O. Harker, A. Salva, Y. Guigoz, and B. Vellas, Screening for Undernutrition in Geriatric Practice: Developing the Short-Fom Mini Nutritional Assessment (MNA-SF), J. Geront, vol.56, pp.366-377, 2001.

Y. Guigoz, The Mini-Nutritional Assessment (MNA®) Review of the Literature -What does it tell us?, J Nutr Health Aging, vol.10, pp.466-487, 2006.

®. Société-des-produits-nestlé, S. A. Vevey, T. Switzerland, ©. Owners, and . Nestlé, Revision 2006. N67200 12/99 10M Pour plus d'informations, 1994.